Domzalski David

VYNE Therapeutics Inc. · PRESIDENT AND CEO

Domzalski David is listed in public filings as director, officer: PRESIDENT AND CEO. This Domzalski David insider trading page organizes Form 4 disclosures, reported purchases and sales, transaction dates, share amounts, related issuers, and historical insider activity so readers can review the person's public trading record in one place. Companies and tickers connected to this insider trading profile include VYNE Therapeutics Inc. (VYNE). Investors use Domzalski David's insider trading disclosures to study buying and selling patterns, position changes, company-specific activity, and the source evidence behind each reported transaction.

Latest Actions

CompanyHolding ValueLast TransactionAmountTransaction PriceCurrent Price
VYNE Therapeutics Inc.VYNE$136k438.8k sharesGrant / ExerciseMay 29, 2026$9.5K30.8k shares$0.31--

Insider Trades History

CompanyHolding ValueLast TransactionAmountTransaction PriceCurrent Price
VYNE Therapeutics Inc.VYNE$240k402k sharesGrant / ExerciseMar 31, 2026$8.5K14.2k shares$0.5975--
VYNE Therapeutics Inc.VYNE$241k416.2k sharesGrant / ExerciseDec 31, 2025$7.4K12.7k shares$0.5801--
VYNE Therapeutics Inc.VYNE$144k428.9k sharesGrant / ExerciseSep 30, 2025$4.2K12.7k shares$0.335--
VYNE Therapeutics Inc.VYNE$729k441.6k sharesGrant / ExerciseJun 30, 2025$20.9K12.7k shares$1.65--
VYNE Therapeutics Inc.VYNE$368k454.2k sharesGrant / ExerciseJun 2, 2025$7.0K8.7k shares$0.81--
VYNE Therapeutics Inc.VYNE$704k445.6k sharesGrant / ExerciseMar 31, 2025$48.2K30.5k shares$1.58--
VYNE Therapeutics Inc.VYNE$2.0M730k sharesGrant / ExerciseJan 21, 2025$2.0M730k shares$2.77--
VYNE Therapeutics Inc.VYNE$1.6M476.1k sharesGrant / ExerciseDec 31, 2024$82.2K24.5k shares$3.35--
VYNE Therapeutics Inc.VYNE$1.1M500.6k sharesGrant / ExerciseNov 30, 2024$8.2K3.9k shares$2.10--
VYNE Therapeutics Inc.VYNE$934k496.7k sharesGrant / ExerciseSep 30, 2024$1.3K685 shares$1.88--
VYNE Therapeutics Inc.VYNE$955k497.7k sharesGrant / ExerciseJul 1, 2024$1.8K935 shares$1.92--